8-K: Plus Therapeutics Reports Full Year 2023 Results and Outlines 2024 Milestones

Plus Therapeutics announced its full year 2023 financial results, highlighted clinical trial progress, and outlined key objectives for 2024, including plans to advance its lead radiotherapeutic into registrational trials in 2025.

Summary

• Plus Therapeutics reported its financial results for the fourth quarter and full year ended December 31, 2023.
• The company's cash balance was $8.6 million at the end of 2023, down from $18.1 million the previous year.
• Grant revenue for 2023 was $4.9 million, compared to $0.2 million in 2022, primarily from CPRIT funding for rhenium (186Re) obisbemeda development.
• The total operating loss for 2023 was $13.3 million, an improvement from the $19.7 million loss in 2022.
• Net loss for 2023 was $13.3 million, or $4.24 per share, compared to a net loss of $20.3 million, or $11.58 per share, in 2022.
• The company plans to move its lead targeted radiotherapeutic into registrational trials in 2025.
• Plus Therapeutics is advancing clinical trials for rhenium (186Re) obisbemeda in leptomeningeal metastases (LM) and recurrent glioblastoma (rGBM).
• The company anticipates FDA meetings in 2024 to discuss the next steps toward product approval.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the progress in clinical trials, the reduction in operating losses, and the plans for FDA meetings. However, the significant decrease in cash reserves and the ongoing net losses temper the overall sentiment.

Positives

• The company has made significant progress in its clinical trials, particularly with the ReSPECT-LM and ReSPECT-GBM trials.
• The company has secured sufficient funding to operate into the second half of 2025.
• The company has received a significant amount of grant funding from CPRIT.
• The company has achieved Orphan Drug Designation for rhenium (186Re) obisbemeda for the treatment of breast cancer with LM.
• The company has reduced its operating loss compared to the previous year.
• The company is planning multiple FDA meetings to discuss the next steps toward product approval.

Negatives

• The company's cash balance has significantly decreased from $18.1 million to $8.6 million year-over-year.
• The company reported a net loss of $13.3 million for the year ended December 31, 2023.
• The company has a significant accumulated deficit of $480.5 million.

Risks

• The company is in the early stages of product development, and clinical trial results are uncertain.
• The company's ability to raise additional capital is a risk.
• The company faces competition in the cancer diagnostics and therapeutics field.
• The company is subject to regulatory risks and requirements.
• The company is exposed to risks related to intellectual property protection and licensing.
• The company is exposed to risks related to material security breaches or cybersecurity attacks.

Future Outlook

The company intends to move its lead targeted radiotherapeutic into registrational trials in 2025 and plans to hold FDA meetings in 2024 to discuss the next steps toward product approval. They also plan to expand manufacturing capacity and continue clinical trials.

Management Comments

• Based on 2023 achievements and planned 2024 milestones, we intend to move our lead targeted radiotherapeutic into registrational trials in 2025, said Marc H. Hedrick M.D., President and Chief Executive Officer of Plus Therapeutics.
• Our ReSPECT clinical trials in both LM and recurrent glioblastoma (rGBM) continue to demonstrate encouraging safety and efficacy signals for rhenium (186Re) obisbemeda and we plan U.S. Food and Drug Administration (FDA) meetings during 2024 to discuss next steps toward product approval.

Industry Context

This announcement is relevant to the broader pharmaceutical industry, particularly in the area of targeted radiotherapeutics for central nervous system cancers. The company's focus on rhenium (186Re) obisbemeda and its clinical trial progress are of interest to investors and competitors in the oncology space.

Comparison to Industry Standards

• Plus Therapeutics is a clinical-stage company, so direct comparisons to revenue-generating pharmaceutical giants are not applicable.
• Companies like Novocure (NVCR) which focuses on tumor treating fields for GBM, and other radiopharmaceutical companies like Lantheus (LNTH) and Telix Pharmaceuticals (TLX) are comparible in terms of development stage and market focus.
• The company's cash burn rate and operating losses are typical for a company in its development stage, but the decrease in cash reserves is a concern.
• The company's progress in clinical trials and its plans for FDA meetings are positive indicators compared to other companies in the same space.

Stakeholder Impact

• Shareholders will be interested in the clinical trial progress and the company's financial performance.
• Employees will be impacted by the company's ability to secure funding and advance its programs.
• Patients with central nervous system cancers may benefit from the company's development of new therapies.
• Suppliers and partners will be impacted by the company's manufacturing and clinical trial activities.
• Creditors will be interested in the company's financial stability and ability to repay debts.

Next Steps

• Present interim safety and feasibility data from the ReSPECT-LM trial at the SNO/ASCO CNS Cancer Conference in August 2024.
• Complete ReSPECT-LM Phase 1 dose escalation trial enrollment and determine the maximum tolerated dose.
• Present complete ReSPECT-LM Phase 1 data at the SNO Annual Meeting in November 2024.
• Implement the Plus CNSide cerebral spinal fluid (CSF)-based tumor cell quantification assay in all ReSPECT-LM trial patients in Q1 2024.
• Hold a 2024 FDA meeting to align on the design for a pivotal Phase 2/3 ReSPECT-LM trial, anticipated to begin in 1H 2025.
• Develop a new, multiple dosing ReSPECT-LM clinical trial in 2024.
• Complete preclinical combination studies of rhenium (186Re) obisbemeda with PD-1 and PD-L1 checkpoint inhibitors.
• Continue to advance the Phase 2 ReSPECT-GBM trial and present data in the second half of 2024.
• Finalize the ReSPECT-GBM pivotal design with the FDA.
• Obtain FDA IND approval to begin enrollment of the ReSPECT-PBC trial for children with high grade glioma and ependymoma.
• Increase GMP manufacturing capacity of rhenium (186Re) obisbemeda.

Key Dates

Keywords

radiotherapeutics, rhenium (186Re) obisbemeda, leptomeningeal metastases, glioblastoma, clinical trials, FDA, cancer, CNS, CPRIT, pharmaceutical